Antibody-antigen complex modeling
Model the 3D structure of antibody-antigen complexes using homology modeling, docking, or hybrid approaches.
- Paratope-epitope prediction
- CDR loop modeling
- Complex structure refinement
CD ComputaBio provides specialized antibody-antigen interaction modeling to characterize paratope-epitope interfaces, predict binding affinity, map critical contacts, and support antibody engineering and design. We combine structural modeling, docking, molecular dynamics, and free energy methods to deliver actionable insights for therapeutic antibody development.
Model the 3D structure of antibody-antigen complexes using homology modeling, docking, or hybrid approaches.
Predict binding free energies and rank antibody variants or antigen mutants using MM-GBSA, FEP, or empirical scoring.
Identify critical residues at the antibody-antigen interface, including H-bonds, hydrophobic contacts, and salt bridges.
Simulate the dynamic behavior of antibody-antigen complexes to assess stability, conformational changes, and binding kinetics.
Provide rational design suggestions for affinity maturation, specificity switching, or developability improvement.
Predict linear and conformational epitopes, and map paratope residues involved in antigen recognition.
Build antibody and antigen structures from sequences using template-based or ab initio methods.
Predict the binding orientation and complex structure using specialized antibody-antigen docking algorithms.
Estimate binding affinity using MM-GBSA, MMPBSA, or free energy perturbation methods.
Simulate antibody-antigen complexes to study dynamics, stability, and conformational ensembles.
Identify energetically important residues at the antibody-antigen interface using computational alanine scanning.
Design antibody variants with improved affinity, specificity, or developability using structure-based methods.
Define the antibody and antigen sequences/structures, the specific modeling question (affinity, interface, design), and the intended application.
Build or prepare antibody and antigen structures, assign protonation states, and set up the complex.
Run docking, MD, free energy calculations, or interface analysis as per project scope.
Compile interface maps, energy values, dynamics data, and provide rational design recommendations.
| Research Question | Recommended Analysis | Key Outputs | Decision Support |
|---|---|---|---|
| How does the antibody bind the antigen? | Complex modeling + interface analysis | Binding mode, paratope-epitope map, contacts | Understand mechanism, guide engineering |
| Which antibody variant has higher affinity? | Binding free energy calculation (MM-GBSA/FEP) | Relative binding energies, ranking | Select lead candidates for testing |
| What are the key residues for binding? | Hotspot analysis (alanine scanning) | Energy contribution per residue, hotspots | Guide mutagenesis, affinity maturation |
| How does antigen mutation affect binding? | Complex modeling + energy calculation | Binding energy change, interface perturbation | Explain escape mutants, cross-reactivity |
| Can we improve antibody stability or affinity? | Structure-based design + MD validation | Mutation suggestions, stability assessment | Lead optimization, developability |
Using MD simulation and MM-GBSA, we identified a hotspot residue in CDR-H3. A single mutation improved predicted affinity by 2.5 kcal/mol, which was confirmed by SPR (KD improved from 12 nM to 1.2 nM).
We modeled the antibody-antigen complex and mapped the conformational epitope, identifying critical residues for binding. This supported biosimilar characterization and regulatory submission.
It is a computational approach to predict and analyze the structural and energetic basis of antibody-antigen recognition, including binding mode, affinity, and interface hotspots.
We need antibody and antigen sequences (FASTA) or 3D structures. Additional data like binding affinities or epitope information can improve accuracy.
Yes, we use MM-GBSA, MMPBSA, and free energy perturbation (FEP) to estimate binding affinities and rank antibody variants.
It identifies key residues for binding, guides affinity maturation, predicts the impact of mutations, and supports developability assessment.
Yes, we can build homology models of antibodies and antigens and then dock or refine the complex structure.
Share your antibody and antigen sequences or structures, and our team will design a tailored interaction modeling plan to accelerate your therapeutic development.
Submit Project DetailsSubmit your project details below, and our team will respond within 24 hours.
Talk to our technical team about your project!
I Want To Talk